Skip to main content

History Timeline

September 5, 1998

Emergent’s first day of business. The company partnered with the U.S. government in a number of ways including:

  • Supplying anthrax vaccine for members of the military
  • Updating security at the Lansing site
  • Performing facility enhancements
  • Investing in BioThrax improvements

 

September 5, 1998

Emergent’s first day of business. The company partnered with the U.S. government in a number of ways including:

  • Supplying anthrax vaccine for members of the military
  • Updating security at the Lansing site
  • Performing facility enhancements
  • Investing in BioThrax improvements

 

Lansing Renovation Approved by FDA

Contract Filler and Distribution of BioThrax Approved by FDA

2003—2010 

After multiple acquisitions, a single Emergent brand and mission is established.

2003—2010 

After multiple acquisitions, a single Emergent brand and mission is established.

Antex Biologics Acquired

Microscience Ltd Acquired

Vivacs GmbH Acquired

BioThrax Approved by the FDA for Five-dose, Intramuscular route

November 15, 2006 

Emergent BioSolutions’ common stock begins trading on the New York Stock Exchange under the symbol EBS.

November 15, 2006 

Emergent BioSolutions’ common stock begins trading on the New York Stock Exchange under the symbol EBS.

2008—2015 

BioThrax Refinement and Ex-US Licensure Expansion

2008—2015 

BioThrax Refinement and Ex-US Licensure Expansion

BioThrax Approved in India

BioThrax Shelf Life Extended to 4 Years

Trubion Pharmaceuticals Acquired

BioThrax Approved in Singapore

VAX161C Pandemic Influenza vaccine candidate rights secured

June 18, 2012 

Biomedical Advanced Research and Development Authority (BARDA) and Emergent Partner to Establish Center for Innovation in Advanced Development and Manufacturing.

June 18, 2012 

Biomedical Advanced Research and Development Authority (BARDA) and Emergent Partner to Establish Center for Innovation in Advanced Development and Manufacturing.

2012—2016 

Expanding our product portfolio, manufacturing capabilities, platforms and technologies to protect life from public health threats.

2012—2016 

Expanding our product portfolio, manufacturing capabilities, platforms and technologies to protect life from public health threats.

RSDL Product Acquired

BioThrax Approved in Germany

Acquisition of Cangene Corporation Completed

Antibacterial Technology Acquired

Emergard® auto-injector platform

CIADM Task Order Received for the Production of an MVA Ebola Zaire Vaccine Candidate

FDA Approved BioThrax for Post-Exposure Prophylaxis

Antiviral Technology Acquired

FDA approved Anthrasil for Use in the Treatment of Inhalational Anthrax

August 1, 2016

Emergent BioSolutions completed a tax-free spin-off of its Biosciences business into a separate, stand-alone publicly-traded company, Aptevo Therapeutics.

August 1, 2016

Emergent BioSolutions completed a tax-free spin-off of its Biosciences business into a separate, stand-alone publicly-traded company, Aptevo Therapeutics.

August 15, 2016

The FDA approved our supplemental Biologics License Application (sBLA) for the large scale manufacturing of BioThrax in Building 55, located on our Lansing, Michigan campus. This milestone was the culmination of more than a decade of investment and collaboration with BARDA.

August 15, 2016

The FDA approved our supplemental Biologics License Application (sBLA) for the large scale manufacturing of BioThrax in Building 55, located on our Lansing, Michigan campus. This milestone was the culmination of more than a decade of investment and collaboration with BARDA.

November 16, 2016

10 year anniversary of Emergent BioSolutions’ common stock trading on the New York Stock Exchange.

November 16, 2016

10 year anniversary of Emergent BioSolutions’ common stock trading on the New York Stock Exchange.

Trademark Legend
Emergent BioSolutions, Protected by Emergent BioSolutions™, Anthrasil™, BAT®, BioThrax®, Emergard®, MVAtor™, NuThrax™, PreviThrax™, and RSDL® and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries.